RU2706729C2 - Способы лечения хронической обструктивной болезни легких с использованием бенрализумаба - Google Patents

Способы лечения хронической обструктивной болезни легких с использованием бенрализумаба Download PDF

Info

Publication number
RU2706729C2
RU2706729C2 RU2016118425A RU2016118425A RU2706729C2 RU 2706729 C2 RU2706729 C2 RU 2706729C2 RU 2016118425 A RU2016118425 A RU 2016118425A RU 2016118425 A RU2016118425 A RU 2016118425A RU 2706729 C2 RU2706729 C2 RU 2706729C2
Authority
RU
Russia
Prior art keywords
copd
benralizumab
administration
patient
aspects
Prior art date
Application number
RU2016118425A
Other languages
English (en)
Russian (ru)
Other versions
RU2016118425A3 (https=
RU2016118425A (ru
Inventor
ДЕР МЕРВЕ Рене ВАН
Кристин УОРД
Убалдо МАРТИН
Лорин РОСКОС
Бин Ван
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2016118425A publication Critical patent/RU2016118425A/ru
Publication of RU2016118425A3 publication Critical patent/RU2016118425A3/ru
Application granted granted Critical
Publication of RU2706729C2 publication Critical patent/RU2706729C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016118425A 2013-10-15 2014-10-14 Способы лечения хронической обструктивной болезни легких с использованием бенрализумаба RU2706729C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361891175P 2013-10-15 2013-10-15
US61/891,175 2013-10-15
US201461970126P 2014-03-25 2014-03-25
US61/970,126 2014-03-25
PCT/US2014/060432 WO2015057668A1 (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Publications (3)

Publication Number Publication Date
RU2016118425A RU2016118425A (ru) 2017-11-21
RU2016118425A3 RU2016118425A3 (https=) 2018-07-19
RU2706729C2 true RU2706729C2 (ru) 2019-11-20

Family

ID=52809872

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016118425A RU2706729C2 (ru) 2013-10-15 2014-10-14 Способы лечения хронической обструктивной болезни легких с использованием бенрализумаба

Country Status (12)

Country Link
US (4) US20150104447A1 (https=)
EP (2) EP3485902A1 (https=)
JP (3) JP2016534996A (https=)
KR (1) KR20160061352A (https=)
CN (2) CN113230399A (https=)
AU (2) AU2014334563A1 (https=)
BR (1) BR112016008082A2 (https=)
CA (1) CA2925402A1 (https=)
MX (2) MX2016004329A (https=)
RU (1) RU2706729C2 (https=)
SG (2) SG10201807318RA (https=)
WO (1) WO2015057668A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2687043C2 (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR20210094669A (ko) 2013-04-29 2021-07-29 에프. 호프만-라 로슈 아게 인간 fcrn-결합 변형된 항체 및 사용 방법
RU2698969C2 (ru) 2014-01-15 2019-09-02 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с улучшенной способностью связываться с белком а
AU2016272399B2 (en) 2015-06-01 2021-09-09 Kyowa Kirin Co., Ltd. Therapeutic agent and therapeutic method for pulmonary hypertension
CN109544378B (zh) * 2018-10-27 2024-06-25 平安医疗健康管理股份有限公司 一种肺源性心脏病资质认证方法、设备及服务器
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
BR112022010934A2 (pt) * 2019-12-06 2022-11-29 Sanofi Biotechnology Métodos para tratar copd administrando um antagonista de il-33
EP3957308A1 (en) 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
WO2023034993A1 (en) * 2021-09-03 2023-03-09 Gleich Gerald J Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120328606A1 (en) * 2011-05-18 2012-12-27 Medimmune, Llc Methods Of Diagnosing And Treating Pulmonary Diseases Or Disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) * 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
EP1176195B1 (en) * 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7404953B2 (en) * 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
HUE036885T2 (hu) * 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
MX2013004212A (es) * 2010-10-15 2013-09-02 Medimmune Ltd Terapias para mejorar la funcion pulmonar.
TWI732259B (zh) * 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
HK1201440A1 (en) * 2011-11-01 2015-09-04 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
US9441046B2 (en) * 2013-08-12 2016-09-13 Astrazeneca Ab Methods for increasing forced expiratory volume in asthmatics using benralizumab

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120328606A1 (en) * 2011-05-18 2012-12-27 Medimmune, Llc Methods Of Diagnosing And Treating Pulmonary Diseases Or Disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BALZANO J. et al., Eosinophilic Inflammation in Stable Chronic Obstructive Pulmonary Disease Relationship with Neutrophils and Airway Function, Am J Respir Crit Care Med, 1999, 160, 5, рр. 1486-92, найдено в 10.07.2018, Интернете [on-line] на сайте *
BALZANO J. et al., Eosinophilic Inflammation in Stable Chronic Obstructive Pulmonary Disease Relationship with Neutrophils and Airway Function, Am J Respir Crit Care Med, 1999, 160, 5, рр. 1486-92, найдено в 10.07.2018, Интернете [on-line] на сайте https://moh-it.pure.elsevier.com/en/publications/eosinophilic-inflammation-in-stable-chronic-obstructive-pulmonary. Результаты исследования II фазы бенрализумаба при ХОБЛ, Astra-Zeneka, 2014, найдено в 10.07.2018, Интернете [on-line] на сайте https://mosmedpreparaty.ru/news/1848. KOLBECK R. et al., MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function, The Journal of allergy and clinical immunology, 2010, 125, 6, pp. 1344-1349, найдено в 10.07.2018, Интернете [on-line] на сайте http://www.biomedsearch.com/nih/MEDI-563-humanized-anti-IL/20513525.html. WECHSLER M.E Novel targeted therapies for eosinophilic disorders, Journal of Allergy and Clinical Immunology, 2012, 130, 3, pp. *

Also Published As

Publication number Publication date
AU2014334563A1 (en) 2016-04-07
SG11201601807XA (en) 2016-04-28
JP6870037B2 (ja) 2021-05-12
MX2016004329A (es) 2016-11-10
RU2016118425A3 (https=) 2018-07-19
KR20160061352A (ko) 2016-05-31
JP2016534996A (ja) 2016-11-10
MX2019013468A (es) 2020-02-12
JP2019203009A (ja) 2019-11-28
JP2021107421A (ja) 2021-07-29
CA2925402A1 (en) 2015-04-23
CN113230399A (zh) 2021-08-10
EP3057609A1 (en) 2016-08-24
US20180291108A1 (en) 2018-10-11
US20200123262A1 (en) 2020-04-23
RU2016118425A (ru) 2017-11-21
SG10201807318RA (en) 2018-09-27
EP3485902A1 (en) 2019-05-22
CN105636607A (zh) 2016-06-01
US20150104447A1 (en) 2015-04-16
EP3057609A4 (en) 2017-03-22
BR112016008082A2 (pt) 2017-10-17
AU2020202333A1 (en) 2020-04-23
US20170107291A1 (en) 2017-04-20
WO2015057668A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
RU2706729C2 (ru) Способы лечения хронической обструктивной болезни легких с использованием бенрализумаба
CN107073114B (zh) 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
US20220040154A1 (en) Use of dexpramipexole for the treatment of moderate to severe asthma
RU2728578C2 (ru) Способы нормализации симптомов астмы с применением бенрализумаба
Shioya et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on cough variant asthma
JP2025106329A (ja) ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法
US11224653B2 (en) Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
HK40008332A (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
US20230348606A1 (en) Methods for treating severe asthma in patients with nasal polyposis
Davies The effect of Obstructive Sleep Apnoea (OSA) on health outcomes in patients with asthma: epidemiology, impact on asthma control, and effect of treatment using Continuous Positive Airway Pressure (CPAP)
US20210095037A1 (en) Methods for treating late-onset asthma using benralizumab
HK1224583A1 (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
HK40090654A (zh) 右旋普拉克索用於治疗中度至重度哮喘的用途
HK1240824A1 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
HK1240824B (en) Use of reslizumab to treat moderate to severe eosinophilic asthma